



X
1. call Brent Johnson
2. Search on STN
3. fax sub.

Listing of the Claims

1. (Cancelled) A composition comprising an amide related to
 - a. a prostaglandin; and
 - b. an amine selected from the group consisting of epinephrine, dopamine, diacetyl dopamine and serotonin.
2. (Cancelled) The composition of claim 1 wherein the prostaglandin is a natural prostaglandin selected from the group consisting of prostaglandin E, prostaglandin E₂, prostaglandin F, prostaglandin F_{2α}, and prostaglandin D₂, or is an analog thereof.
3. (Cancelled) The composition of claim 1 wherein the prostaglandin is prostaglandin F_{2α} or an analog thereof.
4. (Cancelled) The composition of claim 1 wherein the prostaglandin is prostaglandin E₂ or an analog thereof.
5. (Cancelled) The composition of claim 1 wherein the prostaglandin comprises from 0 to 2 double covalent bonds connecting two carbon atoms.
6. (Cancelled) The composition of claim 1 wherein the prostaglandin comprises two double covalent bonds connecting two carbon atoms.
7. (Cancelled) The composition of claim 1 wherein the prostaglandin comprises from 1 to 3 heteroatoms, wherein said heteroatoms comprise S or O, said heteroatoms replacing carbon atoms which are present in prostaglandin E₂, prostaglandin F₂, or prostaglandin D₂.
8. (Cancelled) The composition of claim 1 wherein the prostaglandin comprises a moiety which replaces from 2 to 5 carbon atoms on the terminal end of a ω chain of a natural prostaglandin, said moiety comprising phenyl, naphthyl, benzothienyl, furanyl, or thieryl.
9. (Cancelled) The composition of claim 1 wherein the prostaglandin is prostaglandin F_{2α} and the amine is dopamine.
10. (Cancelled) The composition of claim 1 wherein the prostaglandin is prostaglandin F_{2α} and the amine is diacetyl dopamine.
11. (Cancelled) The composition of claim 1 wherein the prostaglandin is prostaglandin F_{2α} and the amine is serotonin.
12. (Currently Amended) A compound comprising of the formula



or a salt, or ester, or prodrug thereof,

wherein

said compound is not naturally occurring;

the hatched wedge indicates an α configuration and the solid wedge indicates a β configuration;

the dashed line indicates the presence or absence of a double bond;

A and B are both CHOH, or A is CHOH and B is C=O, or B is CHOH and A is C=O;

R¹ is phenyl, indolyl, or monohydroxy or dihydroxy derivatives of phenyl or indolyl;

R² is OH or H;

R³ is n-butyl, n-pentyl, or n-hexyl; cyclohexyl, Ar, or W-Ar;

wherein Ar is phenyl, naphthyl, thiophenyl, furanyl, or benzothiophenyl, or a substituted derivative of phenyl, naphthyl, thiophenyl, furanyl, or benzothiophenyl, wherein from 1 to 3 hydrogen atoms are optionally substituted with halogen, methyl, or trifluoromethyl; and W is N, S, O, or CH₂; and

R⁴ is hydrogen, methyl, ethyl, iso-propyl, or n-propyl.

1 to 3 substituents selected from

the group consisting of F, Cl, Br, I, Me, C₂H₅

13. (Original) The compound of claim 12 wherein R³ is n-butyl, Ar, or W-Ar, wherein Ar is phenyl, naphthyl, or benzothiophenyl.

14. (Original) The compound of claim 12 wherein R³ is n-butyl, Ar, or W-Ar, wherein Ar is phenyl.

15. (Original) The compound of claim 12 wherein R³ is n-butyl or W-Ar, wherein W is O or CH₂, and Ar is phenyl.

16. (Withdrawn) The compound of claim 12 wherein R¹ is 3,4-dihydroxyphenyl and R² is OH.

5
Opt
11
✓
3

Office Messaged
10/20/2020
10/20/2020
10/20/2020


→ wherefrom 1 to 3 hydrogen atoms

17. (Withdrawn) The compound of claim 12 wherein R¹ is 3,4-dihydroxyphenyl, R² is OH, and R⁴ is methyl.


18. (Withdrawn) The compound of claim 12 wherein R¹ is 3,4-dihydroxyphenyl, R² is H, and R⁴ is hydrogen.

19. (Original) The compound of claim 12 wherein R¹ is 5-hydroxyindolyl, R² is H, and R⁴ is hydrogen.


20. (Original) The compound of claim 12 comprising




21. (Original) The compound of claim 12 comprising



22. (Withdrawn) The compound of claim 12 comprising



23. (Withdrawn) The compound of claim 12 comprising



24. (Currently Amended) An ophthalmic composition comprising a compound of claim 12, a therapeutically active agent or a prodrug thereof,
said therapeutically active agent comprising an amide functional group,
wherein
selective hydrolysis of said amide functional group of the therapeutically active agent
produces:
a compound having agonist activity at a prostaglandin receptor and
a compound selected from the group consisting of serotonin and analogs thereof,
dopamine and analogs thereof, and epinephrine and analogs thereof.
25. (Cancelled) The composition of claim 24 wherein said prostaglandin receptor is selected from the group consisting of an FP receptor, an EP₁ receptor, an EP₂ receptor, an EP₄ receptor, a DP receptor, and combinations thereof.
26. (Cancelled) The composition of claim 24 wherein said compound having agonist activity at a prostaglandin receptor is prostaglandin E, prostaglandin E₂, prostaglandin F, prostaglandin F_{2α}, or prostaglandin D₂.
27. (Cancelled) The composition of claim 24 wherein said compound having agonist activity at a prostaglandin receptor is prostaglandin F_{2α}.
28. (Cancelled) The composition of claim 24 wherein selective hydrolysis of said amide functional group produces epinephrine, dopamine, or serotonin.
29. (Cancelled) The composition of claim 24 wherein the therapeutically active agent or said prodrug thereof is selected from the group consisting of
(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(S)-3-hydroxy-oct-1-enyl)-cyclopentyl]-hept-5-enoic acid [2-(5-hydroxy-1*H*-indol-3-yl)-ethyl]-amide;

Acetic acid 2-acetoxy-5-(2-((Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-((E)-(S)-3-hydroxy-oct-1-enyl)-cyclopentyl]-hept-5-enoylamino)-ethyl)-phenyl ester; and

(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(S)-3-hydroxy-oct-1-enyl)-cyclopentyl]-hept-5-enoic acid [2-(3,4-dihydroxy-phenyl)-ethyl]-amide.

30. (Currently Amended) A method of treating glaucoma comprising administering to a mammal suffering from glaucoma or ocular hypertension an effective amount of a compound of claim 12, therapeutically active agent or a pharmaceutically acceptable salt or a prodrug thereof,

said therapeutically active agent consisting of a prostaglandin and a 2-aryl-1-ethylamine coupled by an amide bond.

31. (Cancelled) The method of claim 30 wherein the 2-aryl-1-ethylamine comprises from 1 to 3 hydroxy or acetoxy moieties.

32. (Cancelled) The method of claim 30 wherein said prostaglandin is an FP-related prostaglandin.

33. (Cancelled) The method of claim 30 wherein said prostaglandin is an EP₂-related prostaglandin.

34. (Cancelled) The method of claim 30 wherein said prostaglandin is an EP₄-related prostaglandin.

35. (Cancelled) The method of claim 30 wherein said prostaglandin is a DP-related prostaglandin.

36. (Cancelled) The method of claim 30 wherein said prostaglandin is prostaglandin F_{2α}.

37. (Cancelled) The method of claim 36 wherein said amine is epinephrine, dopamine, or serotonin.

38. (Cancelled) The composition of claim 1 wherein the prostaglandin is prostaglandin F_{2α} and the amine is epinephrine.

39. (Cancelled) The method of claim 30 wherein said prostaglandin is EP₁-related.